About Alembic Pharmaceuticals Limited
Data last updated: 14 July 2026
Alembic Pharmaceuticals Limited is a public limited company based in Vadodara, Gujarat, India, a subsidiary of Nirayu Limited. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 16 June 2010, the company has been in operation for over 16 years.
Registered with ROC Ahmedabad under CIN L24230GJ2010PLC061123. Listed on BSE: 533573 and NSE: APLLTD.
Capital: an authorised share capital of ₹40.5 Cr and a paid-up capital of ₹39.31 Cr. Formerly known as Alembic Pharma Limited. It is led by directors including Chirayu Ramanbhai Amin and Ashok Kumar Barat.
Last AGM: 05 August 2025. Financial statements filed for year ended 31 March 2025. Office: Alembic Road, Vadodara, Gujarat, India – 390003.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹7,344.9 Cr, a growth of 10.08% compared to the previous year. The net worth stands at ₹5,668.98 Cr (up 9.24% YoY). Total assets are valued at ₹8,762.59 Cr (up 12.73% YoY).
The company has a workforce of approximately 15,822 employees as per the latest available data. It operates as a subsidiary of Nirayu Limited.
The company is associated with 2 brands - Alembic Pharmaceuticals, Alembic Limited. As per MCA filings, the company has open charges of ₹600 Cr and satisfied charges of ₹219.36 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website alembicpharmaceuticals.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social Media
-
Registered AddressAlembic Road, Vadodara, Gujarat, India – 390003
-
IndustryPharma, API Manufacturers
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24230GJ2010PLC061123. The current CIN is L24230GJ2010PLC061123, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230GJ2010PLC061123 | Current |
| U24230GJ2010PLC061123 | Previous |
Associated Brands with Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited operates two associated brands: Alembic Pharmaceuticals and Alembic Limited. These brands represent Alembic Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer & supplier of generic pharmaceuticals | alembicpharmaceuticals.com | |
| Active pharmaceutical ingredients are manufactured by Alembic. | alembiclimited.com |
Competitors & Alternatives of Alembic Pharmaceuticals Limited
Brands and companies operating in the same space as Alembic Pharmaceuticals Limited include Merck, Roivant Sciences, AbbVie and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Merck
|
Pharmaceutical products are manufactured and marketed worldwide. | Kenilworth, United Kingdom, United Kingdom | 1891 |
Roivant Sciences
|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | New York, United States, United States | 2014 |
AbbVie
|
Biopharmaceutical research and drug development are conducted globally by AbbVie. | Chicago, United States, United States | 2012 |
Lilly
|
Traditional pharmaceutical medicines are developed for multiple health fields. | United States | 1876 |
Gilead
|
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | Foster City, United States, United States | 1987 |
United Therapeutics
|
Treatments for chronic and life-threatening diseases are developed and commercialized. | Silver Spring, United States, United States | 1998 |
Roche
|
Pharmaceuticals and diagnostics kits are developed for various diseases. | Basel, Switzerland, Switzerland | 1896 |
Ascendis Pharma
|
Long-acting prodrug therapies are developed for endocrine and rare diseases. | Hellerup, Denmark, Denmark | 2007 |
MorphoSys
|
Therapeutic antibodies for cancer and other diseases are developed. | Planegg, Germany, Germany | 1992 |
Vertex Pharmaceuticals
|
Developer of drugs for the treatment of multiple disorders | United States | 1989 |
Business Activity of Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details for Alembic Pharmaceuticals Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is audited by M/s KKC & Associates LLP (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s KKC & Associates LLP (ICAI peer reviewed, certificate valid till 2027-07-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is currently managed by 9 directors, with 9 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chirayu Ramanbhai Amin | Whole-Time Director | 16 Jun 2010 | 16 Years 2 Months | Current |
| Ashok Kumar Barat | Director | 10 Feb 2022 | 4 Years 6 Months | Current |
|
Rajkumar Shreeram Baheti
Also directs:
Alembic Pharmaceuticals Limited
|
Whole-Time Director | 16 Jun 2010 | 16 Years 2 Months | Current |
|
Pranav Chirayu Amin
Also directs:
Alembic Pharmaceuticals Limited, Viramya Packlight Llp, Elecon Engineering Company Limited and 5 more
|
Managing Director | 31 Mar 2011 | 15 Years 4 Months | Current |
|
Shaunak Chirayu Amin
Also directs:
Alembic Pharmaceuticals Limited, Shreno Limited, Fenix Research Labs Private Limited and 1 more
|
Managing Director | 02 May 2013 | 13 Years 3 Months | Current |
| Geeta Amit Goradia | Director | 03 Feb 2025 | 1 Years 6 Months | Current |
Financials of Alembic Pharmaceuticals Limited FY 2026 filings available
Alembic Pharmaceuticals Limited reported revenue of ₹7,344.9 Cr (up 10.08% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7,344.9 Cr | ₹6,672.08 Cr | ₹6,228.63 Cr | ₹5,652.62 Cr | ₹5,305.79 Cr | ₹5,393.13 Cr | ₹4,605.75 Cr |
| Other Income | ₹54.41 Cr | ₹42.55 Cr | ₹28.31 Cr | ₹2.74 Cr | ₹50.46 Cr | ₹10.02 Cr | ₹4.94 Cr |
| Total Income | ₹7,399.31 Cr | ₹6,714.63 Cr | ₹6,256.93 Cr | ₹5,655.36 Cr | ₹5,356.25 Cr | ₹5,403.14 Cr | ₹4,610.69 Cr |
| Cost of Materials Consumed | ₹1,747.38 Cr | ₹1,672.17 Cr | ₹1,403.01 Cr | ₹1,250.08 Cr | ₹1,129.12 Cr | ₹1,185.35 Cr | ₹979.05 Cr |
| Purchases of Stock-in-Trade | ₹508.88 Cr | ₹410.96 Cr | ₹454.91 Cr | ₹380.09 Cr | ₹360.5 Cr | ₹265.92 Cr | ₹270.93 Cr |
| Changes in Inventories | -₹271.81 Cr | -₹289.77 Cr | -₹142.84 Cr | ₹78.65 Cr | -₹43.19 Cr | -₹193.93 Cr | -₹210.59 Cr |
| Employee Benefit Expense | ₹1,731.93 Cr | ₹1,562.34 Cr | ₹1,446.3 Cr | ₹1,169.13 Cr | ₹1,133 Cr | ₹1,051.17 Cr | ₹906.44 Cr |
| Finance Costs | ₹93.63 Cr | ₹78.77 Cr | ₹56.19 Cr | ₹50.17 Cr | ₹17.73 Cr | ₹16.02 Cr | ₹27.16 Cr |
| Depreciation & Amortisation | ₹318.55 Cr | ₹278.58 Cr | ₹272.67 Cr | ₹275.43 Cr | ₹286.78 Cr | ₹183.47 Cr | ₹157.32 Cr |
| Other Expenses | ₹2,510.06 Cr | ₹2,308.15 Cr | ₹2,133.9 Cr | ₹2,066.33 Cr | ₹1,852.2 Cr | ₹1,527.06 Cr | ₹1,436.89 Cr |
| Total Expenses | ₹6,638.62 Cr | ₹6,021.2 Cr | ₹5,624.13 Cr | ₹5,269.86 Cr | ₹4,736.14 Cr | ₹4,035.06 Cr | ₹3,567.22 Cr |
| Profit Before Exceptional Items & Tax | ₹760.69 Cr | ₹693.43 Cr | ₹632.81 Cr | ₹385.51 Cr | ₹620.11 Cr | ₹1,368.08 Cr | ₹1,043.48 Cr |
| Exceptional Items | -₹66.98 Cr | ₹12.87 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹43.65 Cr |
| Profit Before Tax | ₹693.71 Cr | ₹706.3 Cr | ₹632.81 Cr | ₹385.51 Cr | ₹620.11 Cr | ₹1,368.08 Cr | ₹999.83 Cr |
| Total Tax Expense | ₹23.12 Cr | ₹125.16 Cr | ₹16.01 Cr | ₹12.6 Cr | ₹104.46 Cr | ₹253.32 Cr | ₹199.18 Cr |
| Net Profit | ₹670.83 Cr | ₹582.01 Cr | ₹615.82 Cr | ₹341.99 Cr | ₹520.94 Cr | ₹1,146.5 Cr | ₹800.7 Cr |
| attributable to Owners | - | ₹583.42 Cr | ₹615.82 Cr | ₹341.99 Cr | ₹545.68 Cr | ₹1,178.11 Cr | ₹828.82 Cr |
| attributable to NCI | ₹3.94 Cr | -₹1.41 Cr | ₹0 | ₹0 | -₹24.75 Cr | -₹31.61 Cr | -₹28.12 Cr |
| Other Comprehensive Income | ₹24.87 Cr | ₹5.53 Cr | -₹10.84 Cr | ₹13.37 Cr | ₹1.4 Cr | -₹3.69 Cr | -₹1.82 Cr |
| Total Comprehensive Income | ₹695.7 Cr | ₹587.54 Cr | ₹604.98 Cr | ₹355.36 Cr | ₹522.34 Cr | ₹1,142.81 Cr | ₹798.88 Cr |
| EBITDA (computed) | ₹1,172.87 Cr | ₹1,050.78 Cr | ₹961.66 Cr | ₹711.1 Cr | ₹924.62 Cr | ₹1,567.58 Cr | ₹1,227.96 Cr |
| Basic EPS | ₹34.33 | ₹29.68 | ₹31.33 | ₹17.40 | ₹27.76 | ₹60.81 | ₹43.97 |
| Diluted EPS | ₹34.33 | ₹29.68 | ₹31.33 | ₹17.40 | ₹27.76 | ₹60.81 | ₹43.97 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹8,762.59 Cr | ₹7,772.94 Cr | ₹6,445.58 Cr | ₹6,182.83 Cr |
| Non-current Assets | ₹4,189.99 Cr | ₹3,685.14 Cr | ₹3,367.03 Cr | ₹3,272.81 Cr |
| Current Assets | ₹4,542.6 Cr | ₹4,087.8 Cr | ₹3,078.56 Cr | ₹2,910.02 Cr |
| Property, Plant & Equipment | ₹2,843.59 Cr | ₹2,523.53 Cr | ₹2,546.71 Cr | ₹2,398.45 Cr |
| Inventories | ₹2,510.64 Cr | ₹2,288.14 Cr | ₹1,643.54 Cr | ₹1,475.27 Cr |
| Trade Receivables | ₹1,466.3 Cr | ₹1,399.79 Cr | ₹1,024.84 Cr | ₹1,046.4 Cr |
| Cash & Equivalents | ₹196.37 Cr | ₹83.48 Cr | ₹120.21 Cr | ₹75.48 Cr |
| Equity (Net Worth) | ₹5,668.98 Cr | ₹5,189.52 Cr | ₹4,818.2 Cr | ₹4,370.47 Cr |
| Equity Share Capital | ₹39.31 Cr | ₹39.31 Cr | ₹39.31 Cr | ₹39.31 Cr |
| Borrowings (Non-current) | ₹121.92 Cr | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹1,238.93 Cr | ₹1,195.57 Cr | ₹430.45 Cr | ₹635.87 Cr |
| Total Debt (computed) | ₹1,360.85 Cr | ₹1,195.57 Cr | ₹430.45 Cr | ₹635.87 Cr |
| Current Liabilities | ₹2,593.84 Cr | ₹2,412.33 Cr | ₹1,455 Cr | ₹1,636.92 Cr |
| Total Liabilities | ₹3,093.61 Cr | ₹2,583.42 Cr | ₹1,627.39 Cr | ₹1,812.36 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹782.73 Cr | ₹87.97 Cr | ₹803.2 Cr | ₹723.95 Cr | ₹552.3 Cr |
| Investing Cash Flow | -₹506.05 Cr | -₹568.41 Cr | -₹320.61 Cr | -₹447.6 Cr | -₹371.97 Cr |
| Financing Cash Flow | -₹163.79 Cr | ₹443.71 Cr | -₹437.87 Cr | -₹261.97 Cr | -₹217.3 Cr |
| Capital Expenditure | ₹434.62 Cr | ₹563.62 Cr | ₹327.47 Cr | ₹443.41 Cr | ₹425.64 Cr |
| Free Cash Flow (computed) | ₹348.11 Cr | -₹475.65 Cr | ₹475.73 Cr | ₹280.54 Cr | ₹126.66 Cr |
| Dividends Paid | ₹216.22 Cr | ₹216.22 Cr | ₹157.25 Cr | ₹196.56 Cr | ₹275.19 Cr |
| Net Change in Cash | ₹112.89 Cr | -₹36.73 Cr | ₹44.73 Cr | ₹14.39 Cr | -₹36.97 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,847.72 Cr | ₹1,876.31 Cr | ₹1,910.15 Cr | ₹1,710.72 Cr | ₹1,769.64 Cr | ₹1,692.74 Cr | ₹1,647.98 Cr | ₹1,561.73 Cr | ₹1,516.98 Cr | ₹1,630.57 Cr | ₹1,594.93 Cr | ₹1,486.15 Cr |
| Other Income | ₹25.5 Cr | ₹15.5 Cr | ₹6.91 Cr | ₹6.5 Cr | ₹14.19 Cr | ₹9.5 Cr | ₹16.75 Cr | ₹2.1 Cr | ₹3.6 Cr | ₹2.89 Cr | ₹10.15 Cr | ₹11.67 Cr |
| Total Income | ₹1,873.22 Cr | ₹1,891.81 Cr | ₹1,917.06 Cr | ₹1,717.22 Cr | ₹1,783.83 Cr | ₹1,702.25 Cr | ₹1,664.72 Cr | ₹1,563.83 Cr | ₹1,520.58 Cr | ₹1,633.46 Cr | ₹1,605.09 Cr | ₹1,497.81 Cr |
| Cost of Materials Consumed | ₹404.24 Cr | ₹448.73 Cr | ₹463.14 Cr | ₹431.27 Cr | ₹426.2 Cr | ₹446.91 Cr | ₹393.14 Cr | ₹405.93 Cr | ₹337.38 Cr | ₹317.58 Cr | ₹413.87 Cr | ₹334.19 Cr |
| Purchases of Stock-in-Trade | ₹129.79 Cr | ₹143.11 Cr | ₹126.82 Cr | ₹109.16 Cr | ₹92.64 Cr | ₹120.18 Cr | ₹102.64 Cr | ₹95.5 Cr | ₹110.54 Cr | ₹165.45 Cr | ₹88.68 Cr | ₹90.24 Cr |
| Changes in Inventories | -₹1.88 Cr | -₹62.87 Cr | -₹74.04 Cr | -₹133.02 Cr | ₹11.77 Cr | -₹127.55 Cr | -₹66.66 Cr | -₹107.34 Cr | -₹68.55 Cr | -₹22.27 Cr | -₹41.12 Cr | -₹10.91 Cr |
| Employee Benefit Expense | ₹438.91 Cr | ₹432.71 Cr | ₹437.54 Cr | ₹422.77 Cr | ₹393.59 Cr | ₹397.52 Cr | ₹391.47 Cr | ₹379.77 Cr | ₹401.85 Cr | ₹349.28 Cr | ₹346.99 Cr | ₹348.17 Cr |
| Finance Costs | ₹22.56 Cr | ₹23.31 Cr | ₹24.23 Cr | ₹23.52 Cr | ₹24.52 Cr | ₹22.26 Cr | ₹18.81 Cr | ₹13.18 Cr | ₹10.94 Cr | ₹15.17 Cr | ₹15.69 Cr | ₹14.39 Cr |
| Depreciation & Amortisation | ₹88.58 Cr | ₹80.12 Cr | ₹76.07 Cr | ₹73.77 Cr | ₹68.99 Cr | ₹70.05 Cr | ₹70.51 Cr | ₹69.04 Cr | ₹69.48 Cr | ₹69.45 Cr | ₹67.56 Cr | ₹66.18 Cr |
| Other Expenses | ₹648.74 Cr | ₹621.13 Cr | ₹641 Cr | ₹599.2 Cr | ₹573.51 Cr | ₹595.46 Cr | ₹588.13 Cr | ₹551.04 Cr | ₹475.7 Cr | ₹554.16 Cr | ₹578.26 Cr | ₹525.77 Cr |
| Total Expenses | ₹1,730.94 Cr | ₹1,686.24 Cr | ₹1,694.76 Cr | ₹1,526.67 Cr | ₹1,591.22 Cr | ₹1,524.82 Cr | ₹1,498.03 Cr | ₹1,407.12 Cr | ₹1,337.34 Cr | ₹1,448.83 Cr | ₹1,469.94 Cr | ₹1,368.03 Cr |
| Profit Before Exceptional Items & Tax | ₹142.28 Cr | ₹205.57 Cr | ₹222.3 Cr | ₹190.55 Cr | ₹192.61 Cr | ₹177.43 Cr | ₹166.69 Cr | ₹156.71 Cr | ₹183.24 Cr | ₹184.63 Cr | ₹135.15 Cr | ₹129.79 Cr |
| Exceptional Items | -₹24.76 Cr | -₹42.23 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹12.88 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹117.52 Cr | ₹163.34 Cr | ₹222.3 Cr | ₹190.55 Cr | ₹192.61 Cr | ₹177.43 Cr | ₹179.56 Cr | ₹156.71 Cr | ₹183.24 Cr | ₹184.63 Cr | ₹135.15 Cr | ₹129.79 Cr |
| Total Tax Expense | -₹82.91 Cr | ₹29.55 Cr | ₹40 Cr | ₹36.47 Cr | ₹35.31 Cr | ₹40.09 Cr | ₹27.28 Cr | ₹22.49 Cr | ₹4.64 Cr | ₹4.13 Cr | -₹1.92 Cr | ₹9.16 Cr |
| Net Profit | ₹201.54 Cr | ₹131.95 Cr | ₹183.71 Cr | ₹153.63 Cr | ₹156.63 Cr | ₹137.7 Cr | ₹153.15 Cr | ₹134.54 Cr | ₹178.21 Cr | ₹180.46 Cr | ₹136.56 Cr | ₹120.6 Cr |
| attributable to Owners | - | ₹132.97 Cr | ₹184.71 Cr | ₹154.38 Cr | ₹156.89 Cr | ₹138.42 Cr | ₹153.41 Cr | ₹134.71 Cr | ₹178.21 Cr | ₹180.46 Cr | ₹136.56 Cr | ₹120.6 Cr |
| attributable to NCI | ₹1.17 Cr | -₹1.02 Cr | -₹1 Cr | -₹75.3 Lakh | -₹26 Lakh | -₹72 Lakh | -₹26.2 Lakh | -₹16.6 Lakh | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹11.53 Cr | ₹7.95 Cr | ₹4.67 Cr | ₹70 Lakh | ₹5.54 Cr | ₹2.01 Cr | ₹1.31 Cr | -₹3.34 Cr | -₹11.5 Cr | ₹1.03 Cr | ₹56.8 Lakh | -₹93.7 Lakh |
| Total Comprehensive Income | ₹213.07 Cr | ₹139.9 Cr | ₹188.38 Cr | ₹154.33 Cr | ₹162.17 Cr | ₹139.71 Cr | ₹154.46 Cr | ₹131.21 Cr | ₹166.71 Cr | ₹181.49 Cr | ₹137.13 Cr | ₹119.66 Cr |
| EBITDA (computed) | ₹253.42 Cr | ₹309 Cr | ₹322.6 Cr | ₹287.84 Cr | ₹286.12 Cr | ₹269.73 Cr | ₹256.01 Cr | ₹238.93 Cr | ₹263.66 Cr | ₹269.25 Cr | ₹218.4 Cr | ₹210.36 Cr |
| Basic EPS | ₹10.31 | ₹6.76 | ₹9.40 | ₹7.85 | ₹7.98 | ₹7.01 | ₹7.79 | ₹6.85 | ₹9.07 | ₹9.18 | ₹6.95 | ₹6.14 |
| Diluted EPS | ₹10.31 | ₹6.76 | ₹9.40 | ₹7.85 | ₹7.98 | ₹7.01 | ₹7.79 | ₹6.85 | ₹9.07 | ₹9.18 | ₹6.95 | ₹6.14 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹6,651.38 Cr | ₹6,032.63 Cr | ₹5,874.06 Cr | ₹5,149 Cr | ₹4,996.61 Cr | ₹5,051.44 Cr | ₹4,132.55 Cr |
| Other Income | ₹55.9 Cr | ₹47.88 Cr | ₹31.32 Cr | ₹3.55 Cr | ₹49.98 Cr | ₹9.73 Cr | ₹134.75 Cr |
| Total Income | ₹6,707.28 Cr | ₹6,080.51 Cr | ₹5,905.38 Cr | ₹5,152.54 Cr | ₹5,046.58 Cr | ₹5,061.18 Cr | ₹4,267.31 Cr |
| Cost of Materials Consumed | ₹1,747.38 Cr | ₹1,672.17 Cr | ₹1,403.01 Cr | ₹1,250.08 Cr | ₹1,111.75 Cr | ₹1,175.71 Cr | ₹978.13 Cr |
| Purchases of Stock-in-Trade | ₹394.57 Cr | ₹385.14 Cr | ₹449.7 Cr | ₹337.21 Cr | ₹353.35 Cr | ₹279.33 Cr | ₹244.26 Cr |
| Changes in Inventories | -₹121.15 Cr | -₹268.54 Cr | -₹52.36 Cr | ₹72.84 Cr | ₹18.41 Cr | -₹157.13 Cr | -₹176.51 Cr |
| Employee Benefit Expense | ₹1,612.91 Cr | ₹1,466.57 Cr | ₹1,335.91 Cr | ₹1,094.82 Cr | ₹1,028.18 Cr | ₹948.27 Cr | ₹806.37 Cr |
| Finance Costs | ₹86.51 Cr | ₹76.47 Cr | ₹54.47 Cr | ₹49 Cr | ₹16.67 Cr | ₹12.77 Cr | ₹25.19 Cr |
| Depreciation & Amortisation | ₹311 Cr | ₹277.08 Cr | ₹271.14 Cr | ₹272.95 Cr | ₹179.31 Cr | ₹152.6 Cr | ₹135.67 Cr |
| Other Expenses | ₹1,954.96 Cr | ₹1,875.9 Cr | ₹1,739.28 Cr | ₹1,729.71 Cr | ₹1,430.45 Cr | ₹1,233.03 Cr | ₹1,077.4 Cr |
| Total Expenses | ₹5,986.18 Cr | ₹5,484.79 Cr | ₹5,201.15 Cr | ₹4,806.61 Cr | ₹4,138.13 Cr | ₹3,644.58 Cr | ₹3,090.51 Cr |
| Profit Before Exceptional Items & Tax | ₹721.1 Cr | ₹595.72 Cr | ₹704.23 Cr | ₹345.93 Cr | ₹908.45 Cr | ₹1,416.6 Cr | ₹1,176.79 Cr |
| Exceptional Items | -₹66.99 Cr | ₹12.87 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹10 Cr |
| Profit Before Tax | ₹654.11 Cr | ₹608.59 Cr | ₹704.23 Cr | ₹345.93 Cr | ₹908.45 Cr | ₹1,416.6 Cr | ₹1,166.79 Cr |
| Total Tax Expense | ₹13.69 Cr | ₹105.47 Cr | ₹37.75 Cr | -₹79.5 Lakh | ₹114.45 Cr | ₹241.21 Cr | ₹197.39 Cr |
| Net Profit | ₹640.42 Cr | ₹503.12 Cr | ₹666.48 Cr | ₹346.73 Cr | ₹794 Cr | ₹1,175.39 Cr | ₹969.41 Cr |
| Other Comprehensive Income | -₹3.68 Cr | -₹1.07 Cr | -₹14.62 Cr | -₹34.6 Lakh | -₹3.32 Cr | -₹87.5 Lakh | -₹9.33 Cr |
| Total Comprehensive Income | ₹636.74 Cr | ₹502.05 Cr | ₹651.87 Cr | ₹346.38 Cr | ₹790.68 Cr | ₹1,174.52 Cr | ₹960.08 Cr |
| EBITDA (computed) | ₹1,118.61 Cr | ₹949.27 Cr | ₹1,029.84 Cr | ₹667.88 Cr | ₹1,104.44 Cr | ₹1,581.97 Cr | ₹1,337.65 Cr |
| Basic EPS | ₹32.58 | ₹25.60 | ₹33.91 | ₹17.64 | ₹40.39 | ₹60.67 | ₹51.42 |
| Diluted EPS | ₹32.58 | ₹25.60 | ₹33.91 | ₹17.64 | ₹40.39 | ₹60.67 | ₹51.42 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹8,151.25 Cr | ₹7,556.27 Cr | ₹6,398.54 Cr | ₹6,130.42 Cr |
| Non-current Assets | ₹4,120.24 Cr | ₹3,790.07 Cr | ₹3,409.99 Cr | ₹3,350.2 Cr |
| Current Assets | ₹4,001.01 Cr | ₹3,766.2 Cr | ₹2,988.55 Cr | ₹2,780.22 Cr |
| Property, Plant & Equipment | ₹2,828.42 Cr | ₹2,513.47 Cr | ₹2,535.66 Cr | ₹2,377.45 Cr |
| Inventories | ₹2,048.16 Cr | ₹1,976.34 Cr | ₹1,353.07 Cr | ₹1,275.13 Cr |
| Trade Receivables | ₹1,603.75 Cr | ₹1,480.67 Cr | ₹1,340.12 Cr | ₹1,201.2 Cr |
| Cash & Equivalents | ₹22.67 Cr | ₹14.23 Cr | ₹20.13 Cr | ₹21.67 Cr |
| Equity (Net Worth) | ₹5,615.26 Cr | ₹5,194.74 Cr | ₹4,908.91 Cr | ₹4,414.3 Cr |
| Equity Share Capital | ₹39.31 Cr | ₹39.31 Cr | ₹39.31 Cr | ₹39.31 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹1,149.49 Cr | ₹1,142.22 Cr | ₹420.04 Cr | ₹635.07 Cr |
| Total Debt (computed) | ₹1,149.49 Cr | ₹1,142.22 Cr | ₹420.04 Cr | ₹635.07 Cr |
| Current Liabilities | ₹2,356.15 Cr | ₹2,199.6 Cr | ₹1,327.21 Cr | ₹1,551.29 Cr |
| Total Liabilities | ₹2,535.99 Cr | ₹2,361.53 Cr | ₹1,489.63 Cr | ₹1,716.12 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹809.46 Cr | ₹226.57 Cr | ₹772.77 Cr | ₹730.25 Cr | ₹621.15 Cr |
| Investing Cash Flow | -₹483.43 Cr | -₹636.08 Cr | -₹329.02 Cr | -₹460.98 Cr | -₹447.36 Cr |
| Financing Cash Flow | -₹317.59 Cr | ₹403.61 Cr | -₹445.29 Cr | -₹261.16 Cr | -₹216.13 Cr |
| Capital Expenditure | ₹431.97 Cr | ₹563.02 Cr | ₹324.52 Cr | ₹443.26 Cr | ₹408.11 Cr |
| Free Cash Flow (computed) | ₹377.49 Cr | -₹336.45 Cr | ₹448.25 Cr | ₹286.99 Cr | ₹213.04 Cr |
| Dividends Paid | ₹216.22 Cr | ₹216.22 Cr | ₹157.25 Cr | ₹196.56 Cr | ₹275.19 Cr |
| Net Change in Cash | ₹8.44 Cr | -₹5.9 Cr | -₹1.54 Cr | ₹8.11 Cr | -₹42.34 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,718.74 Cr | ₹1,642.24 Cr | ₹1,796.24 Cr | ₹1,494.17 Cr | ₹1,570.64 Cr | ₹1,406.09 Cr | ₹1,580.35 Cr | ₹1,475.56 Cr | ₹1,474.55 Cr | ₹1,588.39 Cr | ₹1,478.84 Cr | ₹1,332.27 Cr |
| Other Income | ₹25.88 Cr | ₹10.73 Cr | ₹11.49 Cr | ₹7.79 Cr | ₹13.21 Cr | ₹15.46 Cr | ₹16.06 Cr | ₹3.15 Cr | ₹7.22 Cr | ₹3.3 Cr | ₹8.95 Cr | ₹11.84 Cr |
| Total Income | ₹1,744.62 Cr | ₹1,652.97 Cr | ₹1,807.73 Cr | ₹1,501.96 Cr | ₹1,583.85 Cr | ₹1,421.55 Cr | ₹1,596.41 Cr | ₹1,478.7 Cr | ₹1,481.78 Cr | ₹1,591.69 Cr | ₹1,487.8 Cr | ₹1,344.12 Cr |
| Cost of Materials Consumed | ₹404.24 Cr | ₹448.73 Cr | ₹463.14 Cr | ₹431.27 Cr | ₹426.2 Cr | ₹446.91 Cr | ₹393.14 Cr | ₹405.93 Cr | ₹337.38 Cr | ₹317.58 Cr | ₹413.87 Cr | ₹334.19 Cr |
| Purchases of Stock-in-Trade | ₹94.37 Cr | ₹104.73 Cr | ₹97.97 Cr | ₹97.5 Cr | ₹89.54 Cr | ₹105.13 Cr | ₹96.1 Cr | ₹94.36 Cr | ₹109.2 Cr | ₹164.87 Cr | ₹85.68 Cr | ₹89.95 Cr |
| Changes in Inventories | ₹16.32 Cr | -₹48.77 Cr | ₹22.8 Cr | -₹111.5 Cr | ₹34.06 Cr | -₹173.73 Cr | -₹17.19 Cr | -₹111.68 Cr | -₹25.25 Cr | ₹10.15 Cr | -₹30.07 Cr | -₹7.2 Cr |
| Employee Benefit Expense | ₹407.02 Cr | ₹401.36 Cr | ₹408.12 Cr | ₹396.4 Cr | ₹373.27 Cr | ₹369.18 Cr | ₹367.61 Cr | ₹356.51 Cr | ₹354.92 Cr | ₹327.11 Cr | ₹326.41 Cr | ₹327.47 Cr |
| Finance Costs | ₹19.42 Cr | ₹21.65 Cr | ₹22.81 Cr | ₹22.64 Cr | ₹23.71 Cr | ₹21.79 Cr | ₹18.28 Cr | ₹12.69 Cr | ₹10.13 Cr | ₹14.66 Cr | ₹15.39 Cr | ₹14.29 Cr |
| Depreciation & Amortisation | ₹82.31 Cr | ₹79.67 Cr | ₹75.64 Cr | ₹73.37 Cr | ₹68.59 Cr | ₹69.69 Cr | ₹70.12 Cr | ₹68.68 Cr | ₹69.12 Cr | ₹69.08 Cr | ₹67.18 Cr | ₹65.75 Cr |
| Other Expenses | ₹522.72 Cr | ₹464.59 Cr | ₹500.9 Cr | ₹466.76 Cr | ₹476.92 Cr | ₹478.78 Cr | ₹481.2 Cr | ₹439.01 Cr | ₹410.11 Cr | ₹431.53 Cr | ₹475.5 Cr | ₹422.13 Cr |
| Total Expenses | ₹1,546.4 Cr | ₹1,471.96 Cr | ₹1,591.38 Cr | ₹1,376.44 Cr | ₹1,492.29 Cr | ₹1,317.74 Cr | ₹1,409.26 Cr | ₹1,265.5 Cr | ₹1,265.61 Cr | ₹1,334.99 Cr | ₹1,353.95 Cr | ₹1,246.59 Cr |
| Profit Before Exceptional Items & Tax | ₹198.22 Cr | ₹181.01 Cr | ₹216.35 Cr | ₹125.52 Cr | ₹91.56 Cr | ₹103.81 Cr | ₹187.15 Cr | ₹213.2 Cr | ₹216.16 Cr | ₹256.7 Cr | ₹133.84 Cr | ₹97.53 Cr |
| Exceptional Items | -₹24.76 Cr | -₹42.23 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹12.88 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹173.46 Cr | ₹138.78 Cr | ₹216.35 Cr | ₹125.52 Cr | ₹91.56 Cr | ₹103.81 Cr | ₹200.02 Cr | ₹213.2 Cr | ₹216.16 Cr | ₹256.7 Cr | ₹133.84 Cr | ₹97.53 Cr |
| Total Tax Expense | -₹69.61 Cr | ₹24.31 Cr | ₹36.99 Cr | ₹22 Cr | ₹16.22 Cr | ₹18 Cr | ₹34.24 Cr | ₹37.01 Cr | ₹14.29 Cr | ₹23.46 Cr | ₹0 | ₹0 |
| Net Profit | ₹243.07 Cr | ₹114.47 Cr | ₹179.36 Cr | ₹103.52 Cr | ₹75.34 Cr | ₹85.81 Cr | ₹165.78 Cr | ₹176.19 Cr | ₹201.87 Cr | ₹233.24 Cr | ₹133.84 Cr | ₹97.53 Cr |
| Other Comprehensive Income | ₹44 Lakh | ₹2.19 Cr | -₹5.92 Cr | -₹39 Lakh | ₹1.82 Cr | ₹10.8 Lakh | ₹21.6 Lakh | -₹3.22 Cr | -₹12.68 Cr | ₹16.2 Lakh | -₹2.01 Cr | -₹8.6 Lakh |
| Total Comprehensive Income | ₹243.51 Cr | ₹116.66 Cr | ₹173.44 Cr | ₹103.13 Cr | ₹77.16 Cr | ₹85.92 Cr | ₹166 Cr | ₹172.97 Cr | ₹189.19 Cr | ₹233.41 Cr | ₹131.83 Cr | ₹97.44 Cr |
| EBITDA (computed) | ₹299.95 Cr | ₹282.33 Cr | ₹314.8 Cr | ₹221.53 Cr | ₹183.86 Cr | ₹195.29 Cr | ₹275.55 Cr | ₹294.57 Cr | ₹295.41 Cr | ₹340.45 Cr | ₹216.41 Cr | ₹177.57 Cr |
| Basic EPS | ₹12.37 | ₹5.82 | ₹9.12 | ₹5.27 | ₹3.83 | ₹4.37 | ₹8.43 | ₹8.96 | ₹10.27 | ₹11.87 | ₹6.81 | ₹4.96 |
| Diluted EPS | ₹12.37 | ₹5.82 | ₹9.12 | ₹5.27 | ₹3.83 | ₹4.37 | ₹8.43 | ₹8.96 | ₹10.27 | ₹11.87 | ₹6.81 | ₹4.96 |
Shareholding Pattern of Alembic Pharmaceuticals Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 69.74%, foreign institutional investors hold 4.25%, domestic institutional investors hold 16.18%, retail and other public shareholders hold 9.83% of Alembic Pharmaceuticals Limited. The company had 86,432 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 69.74% | 69.74% | 69.74% | 69.67% | 69.67% | 69.61% |
| Public | 30.26% | 30.26% | 30.26% | 30.33% | 30.33% | 30.39% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 69.74% | 69.67% | 69.61% | 69.61% | 69.61% | 69.48% | 72.97% | 72.97% | 72.93% | 72.68% | 74.13% |
| Public | 30.26% | 30.33% | 30.39% | 30.39% | 30.39% | 30.52% | 27.03% | 27.03% | 27.07% | 27.32% | 25.87% |
| Promoter change (YoY, %pts) | +0.07 | +0.06 | +0.00 | +0.00 | +0.13 | -3.49 | +0.00 | +0.04 | +0.25 | -1.45 | - |
Board & Governance of Alembic Pharmaceuticals Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Alembic Pharmaceuticals Limited has 8 directors - 4 independent and 4 executive. The board is chaired by Chirayu Ramanbhai Amin.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Chirayu Ramanbhai Amin | Executive Director · CEO · Chairperson | 2010-06-16 | 3 |
| Pranav Chirayu Amin | Executive Director · MD | 2011-03-31 | 3 |
| Shaunak Chirayu Amin | Executive Director · MD | 2013-05-02 | 1 |
| Ashok Kumar Barat | Non-Executive - Independent Director | 2022-02-10 | 7 |
| Jai Shishir Diwanji | Non-Executive - Independent Director | 2023-05-05 | 5 |
| Manish Santoshkumar Kejriwal | Non-Executive - Independent Director | 2024-03-31 | 4 |
| Geeta Amit Goradia | Non-Executive - Independent Director | 2025-02-03 | 1 |
| Raj Kumar Baheti | Executive Director | 2010-06-16 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Ashok Kumar Barat (Chairperson), Jai Shishir Diwanji, Geeta Amit Goradia |
| Nomination and remuneration committee | Manish Santoshkumar Kejriwal (Chairperson), Ashok Kumar Barat, Jai Shishir Diwanji, Geeta Amit Goradia |
| Stakeholders Relationship Committee | Jai Shishir Diwanji (Chairperson), Pranav Chirayu Amin, Raj Kumar Baheti |
| Risk Management Committee | Ashok Kumar Barat (Chairperson), Pranav Chirayu Amin, Raj Kumar Baheti |
| Corporate Social Responsibility Committee | Chirayu Ramanbhai Amin (Chairperson), Ashok Kumar Barat, Manish Santoshkumar Kejriwal |
Group Structure of Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has 1 associated company. This group structure data is as of FY 2023. The corporate group structure reflects Alembic Pharmaceuticals Limited's business expansion strategy and organizational complexity.
Charges & Borrowings of Alembic Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2011 | Others | ₹600 Cr | Open |
| 19 Nov 2021 | Hdfc Bank Limited | ₹5 Cr | Satisfied |
| 26 Jul 2021 | Yes Bank Limited | ₹10 Cr | Satisfied |
| 08 May 2014 | Bank of Baroda | ₹1.36 Cr | Satisfied |
| 02 Dec 2011 | Dbs Bank Limited | ₹78 Cr | Satisfied |
Total charge records: 8 View all charges
Employees and EPFO Compliance at Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited has a workforce of 15,822 employees as of Feb 11, 2025.
Employee and EPFO history for Alembic Pharmaceuticals Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Alembic Pharmaceuticals Limited
GST registrations and filing compliance for Alembic Pharmaceuticals Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Alembic Pharmaceuticals Limited
Credit ratings, litigation, and regulatory alerts for Alembic Pharmaceuticals Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Alembic Pharmaceuticals Limited
MSME payment history for Alembic Pharmaceuticals Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Alembic Pharmaceuticals Limited
Corporate group structure for Alembic Pharmaceuticals Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Alembic Pharmaceuticals Limited
MCA filings and documents for Alembic Pharmaceuticals Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Alembic Pharmaceuticals Limited
Recent News on Alembic Pharmaceuticals Limited
Frequently Asked Questions about Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 16 June 2010 (16+ years old) and is registered under CIN L24230GJ2010PLC061123. Listed on BSE: 533573 and NSE: APLLTD. The company has 15,822 employees.
Alembic Pharmaceuticals Limited reported revenue of ₹7,344.9 Cr for FY 2026 (up 10.08% YoY) based on consolidated NSE filings.
The current directors of Alembic Pharmaceuticals Limited are:
- Chirayu Ramanbhai Amin - Whole-Time Director
- Ashok Kumar Barat - Director
- Rajkumar Shreeram Baheti - Whole-Time Director
- Pranav Chirayu Amin - Managing Director
- Shaunak Chirayu Amin - Managing Director
- Geeta Amit Goradia - Director
- Manish Santoshkumar Kejriwal - Director
- Jai Shishir Diwanji - Director
- Sujit Jaysukh Bhayani - Additional Director
The primary industry of Alembic Pharmaceuticals Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.
Yes. Alembic Pharmaceuticals Limited is listed on both BSE (code: 533573) and NSE (symbol: APLLTD).
Alembic Pharmaceuticals Limited can be reached at the registered office: Alembic Road, Vadodara, Gujarat, India – 390003, or through the website alembicpharmaceuticals.com.